Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients

(1) Background: CAR-T-cell therapy is a novel therapeutic option for patients with relapsed/refractory diffuse large B-cell lymphoma (<i>r</i>/<i>r</i> DLBCL). The parameters that predict a favorable outcome after CAR-T-cell treatment are a matter of ongoing exploration. (2)...

Full description

Bibliographic Details
Main Authors: Anna Nydegger, Urban Novak, Marie-Noëlle Kronig, Myriam Legros, Sacha Zeerleder, Yara Banz, Ulrike Bacher, Thomas Pabst
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
CAR-T-cell therapy
diffuse large B-cell lymphoma (DLBCL)
secondary DLBCL
prognosis
relapse
Online Access:https://www.mdpi.com/2072-6694/13/23/6073

Similar Items

Similar Items